Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2015-12-31 | 85143161 | u5 |
| ifrs-full:Assets | 2015-06-30 | 95544801 | u5 |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/55366223/ZG9rdW1lbnRsYWdlcjovLzAzLzViLzUxL2ZhLzE3LzY1YzktNDlhYi1hZGEwLWJjMTlmY2MyNzhhZA.xml
Separator
The full data:
<?xml version="1.0" encoding="UTF-8"?><xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:f="http://xbrl.dcca.dk/sob" xmlns:h="http://xbrl.dcca.dk/mrv" xmlns:g="http://xbrl.dcca.dk/arr" xmlns:e="http://xbrl.dcca.dk/cmn" xmlns:d="http://xbrl.dcca.dk/fsa" xmlns:c="http://xbrl.dcca.dk/gsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:b="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByFunction" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://xbrl.dcca.dk/entryBalanceSheetAccountFormIncomeStatementByFunction http://archprod.service.eogs.dk/taxonomy/20140701/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByFunctionIncludingManagementsReviewStatisticsAndTax20140701.xsd"><link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20140701/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByFunctionIncludingManagementsReviewStatisticsAndTax20140701.xsd"/><c:InformationOnTypeOfSubmittedReport contextRef="c1">Ã
rsrapport</c:InformationOnTypeOfSubmittedReport><c:IdentificationNumberCvrOfSubmittingEnterprise contextRef="c1">30700228</c:IdentificationNumberCvrOfSubmittingEnterprise><c:NameOfSubmittingEnterprise contextRef="c1">Ernst & Young Godkendt Revisionspartnerselskab</c:NameOfSubmittingEnterprise><c:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="c1">Osvald Helmuths Vej 4</c:AddressOfSubmittingEnterpriseStreetAndNumber><c:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="c1">Postboks 250, 2000 Frederiksberg</c:AddressOfSubmittingEnterprisePostcodeAndTown><c:ReportingPeriodStartDate contextRef="c1">2015-07-01</c:ReportingPeriodStartDate><c:ReportingPeriodEndDate contextRef="c1">2015-12-31</c:ReportingPeriodEndDate><c:DateOfApprovalOfReport contextRef="c1">2016-06-01</c:DateOfApprovalOfReport><c:IdentificationNumberCvrOfReportingEntity contextRef="c1">32266355</c:IdentificationNumberCvrOfReportingEntity><c:NameOfReportingEntity contextRef="c1">Orphazyme ApS</c:NameOfReportingEntity><c:AddressOfReportingEntityStreetName contextRef="c1">Ole Maaløes Vej </c:AddressOfReportingEntityStreetName><c:AddressOfReportingEntityStreetBuildingIdentifier contextRef="c1">3</c:AddressOfReportingEntityStreetBuildingIdentifier><c:AddressOfReportingEntityPostCodeIdentifier contextRef="c1">2200</c:AddressOfReportingEntityPostCodeIdentifier><c:AddressOfReportingEntityDistrictName contextRef="c1">Copenhagen N</c:AddressOfReportingEntityDistrictName><c:DateOfFoundationOfReportingEntity contextRef="c1">2009-06-19</c:DateOfFoundationOfReportingEntity><c:RegisteredOfficeOfReportingEntity contextRef="c1">Copenhagen</c:RegisteredOfficeOfReportingEntity><c:TelephoneNumberOfReportingEntity contextRef="c1">70702980</c:TelephoneNumberOfReportingEntity><c:HomepageOfReportingEntity contextRef="c1">www.orphazyme.com</c:HomepageOfReportingEntity><c:NameOfFinancialInstitution contextRef="c1">Dansk Bank</c:NameOfFinancialInstitution><c:AddressOfAuditorStreetName contextRef="c106">Osvald Helmuths Vej </c:AddressOfAuditorStreetName><c:AddressOfAuditorStreetBuildingIdentifier contextRef="c106">4</c:AddressOfAuditorStreetBuildingIdentifier><c:AddressOfAuditorPostCodeIdentifier contextRef="c106">2000</c:AddressOfAuditorPostCodeIdentifier><c:AddressOfAuditorDistrictName contextRef="c106">Frederiksberg</c:AddressOfAuditorDistrictName><c:AddressOfAuditorCountry contextRef="c1">Danmark</c:AddressOfAuditorCountry><c:TelephoneNumberOfAuditor contextRef="c1">+45 73 23 30 00</c:TelephoneNumberOfAuditor><c:DateOfGeneralMeeting contextRef="c1">2016-06-01</c:DateOfGeneralMeeting><c:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="c1">Georges Gemayel</c:NameAndSurnameOfChairmanOfGeneralMeeting><d:ClassOfReportingEntity contextRef="c1">Regnskabsklasse B</d:ClassOfReportingEntity><e:TypeOfAuditorAssistance contextRef="c1">Revisionspåtegning</e:TypeOfAuditorAssistance><f:DateOfApprovalOfAnnualReport contextRef="c1">2016-06-01</f:DateOfApprovalOfAnnualReport><g:SignatureOfAuditorsDate contextRef="c1">2016-06-01</g:SignatureOfAuditorsDate><f:PlaceOfSignatureOfStatement contextRef="c1">Copenhagen, </f:PlaceOfSignatureOfStatement><e:NameAndSurnameOfMemberOfExecutiveBoard contextRef="c76">Anders Mørkeberg Hinsby</e:NameAndSurnameOfMemberOfExecutiveBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c33">Georges Gemayel</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:TitleOfMemberOfSupervisoryBoard contextRef="c33">Chairman</e:TitleOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c49">Patrick Johan Hendrik Krol</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c50">Rémi Pascal Louis Droller</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c51">Nanna Liebach Lüneborg</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c52">Martin Bonde</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c53">Martin Rahbek Kornum</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c54">Sten Verland</e:NameAndSurnameOfMemberOfSupervisoryBoard><e:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="c55">Bo Jesper Hansen</e:NameAndSurnameOfMemberOfSupervisoryBoard><g:SignatureOfAuditorsPlace contextRef="c1">Copenhagen, </g:SignatureOfAuditorsPlace><e:NameAndSurnameOfAuditor contextRef="c106">Christian Schwenn Johansen</e:NameAndSurnameOfAuditor><e:DescriptionOfAuditor contextRef="c106">State Authorised Public Accountant</e:DescriptionOfAuditor><d:AdministrativeExpenses contextRef="c1" unitRef="u5" decimals="0">2052450</d:AdministrativeExpenses><d:AdministrativeExpenses contextRef="c4" unitRef="u5" decimals="0">4055946</d:AdministrativeExpenses><d:ResearchExpenditure contextRef="c1" unitRef="u5" decimals="0">26948247</d:ResearchExpenditure><d:ResearchExpenditure contextRef="c4" unitRef="u5" decimals="0">33046514</d:ResearchExpenditure><d:OtherFinanceIncome contextRef="c1" unitRef="u5" decimals="0">80093</d:OtherFinanceIncome><d:OtherFinanceIncome contextRef="c4" unitRef="u5" decimals="0">34264</d:OtherFinanceIncome><d:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">40009</d:OtherFinanceExpenses><d:OtherFinanceExpenses contextRef="c4" unitRef="u5" decimals="0">764928</d:OtherFinanceExpenses><d:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c1" unitRef="u5" decimals="0">-28960613</d:ProfitLossFromOrdinaryActivitiesBeforeTax><d:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="c4" unitRef="u5" decimals="0">-37833124</d:ProfitLossFromOrdinaryActivitiesBeforeTax><d:ProfitLoss contextRef="c1" unitRef="u5" decimals="0">-26210613</d:ProfitLoss><d:ProfitLoss contextRef="c4" unitRef="u5" decimals="0">-31958124</d:ProfitLoss><d:ProfitLoss contextRef="c194" unitRef="u5" decimals="0">-26210613</d:ProfitLoss><d:ProfitLoss contextRef="c195" unitRef="u5" decimals="0">-31958124</d:ProfitLoss><d:FixturesFittingsToolsAndEquipment contextRef="c7" unitRef="u5" decimals="0">1211755</d:FixturesFittingsToolsAndEquipment><d:FixturesFittingsToolsAndEquipment contextRef="c5" unitRef="u5" decimals="0">1419407</d:FixturesFittingsToolsAndEquipment><d:LeaseholdImprovements contextRef="c7" unitRef="u5" decimals="0">274874</d:LeaseholdImprovements><d:LeaseholdImprovements contextRef="c5" unitRef="u5" decimals="0">328903</d:LeaseholdImprovements><d:PropertyPlantAndEquipment contextRef="c7" unitRef="u5" decimals="0">1486629</d:PropertyPlantAndEquipment><d:PropertyPlantAndEquipment contextRef="c5" unitRef="u5" decimals="0">1748310</d:PropertyPlantAndEquipment><d:OtherLongtermReceivables contextRef="c7" unitRef="u5" decimals="0">2750000</d:OtherLongtermReceivables><d:OtherLongtermReceivables contextRef="c5" unitRef="u5" decimals="0">5875000</d:OtherLongtermReceivables><d:DepositsLongtermInvestmentsAndReceivables contextRef="c7" unitRef="u5" decimals="0">211161</d:DepositsLongtermInvestmentsAndReceivables><d:DepositsLongtermInvestmentsAndReceivables contextRef="c5" unitRef="u5" decimals="0">183978</d:DepositsLongtermInvestmentsAndReceivables><d:LongtermInvestmentsAndReceivables contextRef="c7" unitRef="u5" decimals="0">2961161</d:LongtermInvestmentsAndReceivables><d:LongtermInvestmentsAndReceivables contextRef="c5" unitRef="u5" decimals="0">6058978</d:LongtermInvestmentsAndReceivables><d:NoncurrentAssets contextRef="c7" unitRef="u5" decimals="0">4447790</d:NoncurrentAssets><d:NoncurrentAssets contextRef="c5" unitRef="u5" decimals="0">7807288</d:NoncurrentAssets><d:ShorttermTaxReceivables contextRef="c7" unitRef="u5" decimals="0">5875000</d:ShorttermTaxReceivables><d:ShorttermTaxReceivables contextRef="c5" unitRef="u5" decimals="0">6250000</d:ShorttermTaxReceivables><d:OtherShorttermReceivables contextRef="c7" unitRef="u5" decimals="0">6600171</d:OtherShorttermReceivables><d:OtherShorttermReceivables contextRef="c5" unitRef="u5" decimals="0">3036163</d:OtherShorttermReceivables><d:DeferredIncomeAssets contextRef="c7" unitRef="u5" decimals="0">205903</d:DeferredIncomeAssets><d:DeferredIncomeAssets contextRef="c5" unitRef="u5" decimals="0">290275</d:DeferredIncomeAssets><d:ShorttermReceivables contextRef="c7" unitRef="u5" decimals="0">12681074</d:ShorttermReceivables><d:ShorttermReceivables contextRef="c5" unitRef="u5" decimals="0">9576438</d:ShorttermReceivables><d:CashAndCashEquivalents contextRef="c7" unitRef="u5" decimals="0">68014297</d:CashAndCashEquivalents><d:CashAndCashEquivalents contextRef="c5" unitRef="u5" decimals="0">78161075</d:CashAndCashEquivalents><d:CurrentAssets contextRef="c7" unitRef="u5" decimals="0">80695371</d:CurrentAssets><d:CurrentAssets contextRef="c5" unitRef="u5" decimals="0">87737513</d:CurrentAssets><d:Assets contextRef="c7" unitRef="u5" decimals="0">85143161</d:Assets><d:Assets contextRef="c5" unitRef="u5" decimals="0">95544801</d:Assets><d:ContributedCapital contextRef="c7" unitRef="u5" decimals="0">3345755</d:ContributedCapital><d:ContributedCapital contextRef="c5" unitRef="u5" decimals="0">3218031</d:ContributedCapital><d:RetainedEarnings contextRef="c7" unitRef="u5" decimals="0">71680133</d:RetainedEarnings><d:RetainedEarnings contextRef="c5" unitRef="u5" decimals="0">86523310</d:RetainedEarnings><d:Equity contextRef="c7" unitRef="u5" decimals="0">75025888</d:Equity><d:Equity contextRef="c5" unitRef="u5" decimals="0">89741341</d:Equity><d:ShorttermDebtToBanks contextRef="c7" unitRef="u5" decimals="0">0</d:ShorttermDebtToBanks><d:ShorttermDebtToBanks contextRef="c5" unitRef="u5" decimals="0">245151</d:ShorttermDebtToBanks><d:ShorttermTradePayables contextRef="c7" unitRef="u5" decimals="0">7557981</d:ShorttermTradePayables><d:ShorttermTradePayables contextRef="c5" unitRef="u5" decimals="0">3394496</d:ShorttermTradePayables><d:OtherShorttermPayables contextRef="c7" unitRef="u5" decimals="0">2559292</d:OtherShorttermPayables><d:OtherShorttermPayables contextRef="c5" unitRef="u5" decimals="0">2163813</d:OtherShorttermPayables><d:ShorttermLiabilitiesOtherThanProvisions contextRef="c7" unitRef="u5" decimals="0">10117273</d:ShorttermLiabilitiesOtherThanProvisions><d:ShorttermLiabilitiesOtherThanProvisions contextRef="c5" unitRef="u5" decimals="0">5803460</d:ShorttermLiabilitiesOtherThanProvisions><d:LiabilitiesOtherThanProvisions contextRef="c7" unitRef="u5" decimals="0">10117273</d:LiabilitiesOtherThanProvisions><d:LiabilitiesOtherThanProvisions contextRef="c5" unitRef="u5" decimals="0">5803460</d:LiabilitiesOtherThanProvisions><d:LiabilitiesAndEquity contextRef="c7" unitRef="u5" decimals="0">85143161</d:LiabilitiesAndEquity><d:LiabilitiesAndEquity contextRef="c5" unitRef="u5" decimals="0">95544801</d:LiabilitiesAndEquity><d:Equity contextRef="c312" unitRef="u5" decimals="0">3218031</d:Equity><d:Equity contextRef="c351" unitRef="u5" decimals="0">86523310</d:Equity><d:IncreaseOfCapital contextRef="c313" unitRef="u5" decimals="0">127724</d:IncreaseOfCapital><d:IncreaseOfCapital contextRef="c352" unitRef="u5" decimals="0">11397436</d:IncreaseOfCapital><d:CostRelatedToIncreaseOfCapital contextRef="c313" unitRef="u5" decimals="0">0</d:CostRelatedToIncreaseOfCapital><d:CostRelatedToIncreaseOfCapital contextRef="c352" unitRef="u5" decimals="0">30000</d:CostRelatedToIncreaseOfCapital><d:ProfitLoss contextRef="c352" unitRef="u5" decimals="0">-26210613</d:ProfitLoss><d:Equity contextRef="c314" unitRef="u5" decimals="0">3345755</d:Equity><d:Equity contextRef="c353" unitRef="u5" decimals="0">71680133</d:Equity><d:WagesAndSalaries contextRef="c1" unitRef="u5" decimals="0">6909979</d:WagesAndSalaries><d:WagesAndSalaries contextRef="c4" unitRef="u5" decimals="0">10566745</d:WagesAndSalaries><d:PostemploymentBenefitExpense contextRef="c1" unitRef="u5" decimals="0">466551</d:PostemploymentBenefitExpense><d:PostemploymentBenefitExpense contextRef="c4" unitRef="u5" decimals="0">796885</d:PostemploymentBenefitExpense><d:SocialSecurityContributions contextRef="c1" unitRef="u5" decimals="0">22140</d:SocialSecurityContributions><d:SocialSecurityContributions contextRef="c4" unitRef="u5" decimals="0">33030</d:SocialSecurityContributions><d:OtherEmployeeExpense contextRef="c1" unitRef="u5" decimals="0">10795</d:OtherEmployeeExpense><d:OtherEmployeeExpense contextRef="c4" unitRef="u5" decimals="0">30441</d:OtherEmployeeExpense><d:EmployeeBenefitsExpense contextRef="c1" unitRef="u5" decimals="0">7409465</d:EmployeeBenefitsExpense><d:EmployeeBenefitsExpense contextRef="c4" unitRef="u5" decimals="0">11427101</d:EmployeeBenefitsExpense><d:RemunerationOfManagementCategories contextRef="c1" unitRef="u5" decimals="0">7409465</d:RemunerationOfManagementCategories><d:RemunerationOfManagementCategories contextRef="c4" unitRef="u5" decimals="0">11427101</d:RemunerationOfManagementCategories><d:OtherInterestIncome contextRef="c1" unitRef="u5" decimals="0">6196</d:OtherInterestIncome><d:OtherInterestIncome contextRef="c4" unitRef="u5" decimals="0">34264</d:OtherInterestIncome><d:ExchangeRateProfit contextRef="c1" unitRef="u5" decimals="0">73897</d:ExchangeRateProfit><d:ExchangeRateProfit contextRef="c4" unitRef="u5" decimals="0">0</d:ExchangeRateProfit><d:OtherFinanceIncome contextRef="c1" unitRef="u5" decimals="0">80093</d:OtherFinanceIncome><d:OtherFinanceIncome contextRef="c4" unitRef="u5" decimals="0">34264</d:OtherFinanceIncome><d:InterestExpenseAssignedToAssociates contextRef="c1" unitRef="u5" decimals="0">0</d:InterestExpenseAssignedToAssociates><d:InterestExpenseAssignedToAssociates contextRef="c4" unitRef="u5" decimals="0">607491</d:InterestExpenseAssignedToAssociates><d:OtherInterestExpenses contextRef="c1" unitRef="u5" decimals="0">25527</d:OtherInterestExpenses><d:OtherInterestExpenses contextRef="c4" unitRef="u5" decimals="0">0</d:OtherInterestExpenses><d:ExchangeRateLoss contextRef="c1" unitRef="u5" decimals="0">0</d:ExchangeRateLoss><d:ExchangeRateLoss contextRef="c4" unitRef="u5" decimals="0">129255</d:ExchangeRateLoss><d:OtherAdjustmentsOfFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">14482</d:OtherAdjustmentsOfFinanceExpenses><d:OtherAdjustmentsOfFinanceExpenses contextRef="c4" unitRef="u5" decimals="0">28182</d:OtherAdjustmentsOfFinanceExpenses><d:OtherFinanceExpenses contextRef="c1" unitRef="u5" decimals="0">40009</d:OtherFinanceExpenses><d:OtherFinanceExpenses contextRef="c4" unitRef="u5" decimals="0">764928</d:OtherFinanceExpenses><d:CurrentTaxExpense contextRef="c1" unitRef="u5" decimals="0">-2750000</d:CurrentTaxExpense><d:CurrentTaxExpense contextRef="c4" unitRef="u5" decimals="0">-5875000</d:CurrentTaxExpense><d:TaxExpenseOnOrdinaryActivities contextRef="c1" unitRef="u5" decimals="0">-2750000</d:TaxExpenseOnOrdinaryActivities><d:TaxExpenseOnOrdinaryActivities contextRef="c4" unitRef="u5" decimals="0">-5875000</d:TaxExpenseOnOrdinaryActivities><d:DescriptionOfClassOfIssuedShares contextRef="c72">A</d:DescriptionOfClassOfIssuedShares><d:NominalValueOfIssuedShares contextRef="c72" unitRef="u5" decimals="0">125000</d:NominalValueOfIssuedShares><d:NominalValueOfIssuedShares contextRef="c1294" unitRef="u5" decimals="0">125000</d:NominalValueOfIssuedShares><d:DescriptionOfClassOfIssuedShares contextRef="c72">B</d:DescriptionOfClassOfIssuedShares><d:NominalValueOfIssuedShares contextRef="c72" unitRef="u5" decimals="0">2050208</d:NominalValueOfIssuedShares><d:NominalValueOfIssuedShares contextRef="c1294" unitRef="u5" decimals="0">2050208</d:NominalValueOfIssuedShares><d:DescriptionOfClassOfIssuedShares contextRef="c72">C</d:DescriptionOfClassOfIssuedShares><d:NominalValueOfIssuedShares contextRef="c72" unitRef="u5" decimals="0">1170547</d:NominalValueOfIssuedShares><d:NominalValueOfIssuedShares contextRef="c1294" unitRef="u5" decimals="0">1042823</d:NominalValueOfIssuedShares><d:Equity contextRef="c393" unitRef="u5" decimals="0">2175208</d:Equity><d:Equity contextRef="c396" unitRef="u5" decimals="0">2175208</d:Equity><d:Equity contextRef="c399" unitRef="u5" decimals="0">1629422</d:Equity><d:Equity contextRef="c402" unitRef="u5" decimals="0">565136</d:Equity><d:IncreaseOfCapital contextRef="c394" unitRef="u5" decimals="0">1042823</d:IncreaseOfCapital><d:IncreaseOfCapital contextRef="c397" unitRef="u5" decimals="0">0</d:IncreaseOfCapital><d:IncreaseOfCapital contextRef="c400" unitRef="u5" decimals="0">545786</d:IncreaseOfCapital><d:IncreaseOfCapital contextRef="c403" unitRef="u5" decimals="0">1064286</d:IncreaseOfCapital><d:Equity contextRef="c395" unitRef="u5" decimals="0">3218031</d:Equity><d:Equity contextRef="c398" unitRef="u5" decimals="0">2175208</d:Equity><d:Equity contextRef="c401" unitRef="u5" decimals="0">2175208</d:Equity><d:Equity contextRef="c404" unitRef="u5" decimals="0">1629422</d:Equity><f:IdentificationOfApprovedAnnualReport contextRef="c1">The Board of Directors and the Executive Board have today discussed and approved the annual report of Orphazyme ApS for the financial year 1 July - 31 December 2015.</f:IdentificationOfApprovedAnnualReport><f:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="c1">The annual report is prepared in accordance with the Danish Financial Statements Act.</f:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement><f:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="c1">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of the Company's operations for the financial year 1 July - 31 December 2015.</f:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults><f:ManagementsStatementAboutManagementsReview contextRef="c1">Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.</f:ManagementsStatementAboutManagementsReview><f:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="c1">We recommend that the annual report be approved at the annual general meeting.</f:RecommendationForApprovalOfAnnualReportByGeneralMeeting><g:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="c1">To the shareholders of Orphazyme ApS</g:AddresseeOfAuditorsReportOnAuditedFinancialStatements><g:IdentificationOfAuditedFinancialStatements contextRef="c1">We have audited the financial statements of Orphazyme ApS for the financial year 1 July - 31 December 2015, which comprise an income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.</g:IdentificationOfAuditedFinancialStatements><g:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="c1">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</g:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements><g:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="c1">Our responsibility is to express an opinion on the financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and additional requirements under Danish audit regulations. This requires that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free from material misstatement.
An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Company's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Management, as well as evaluating the overall presentation of the financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Our audit has not resulted in any qualification.</g:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed><g:OpinionOnAuditedFinancialStatements contextRef="c1">In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2015 and of the results of its operations for the financial year 1 July - 31 December 2015 in accordance with the Danish Financial Statements Act.</g:OpinionOnAuditedFinancialStatements><g:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="c1">Pursuant to the Danish Financial Statements Act, we have read the Management's review. We have not performed any other procedures in addition to the audit of the financial statements. On this basis, it is our opinion that the information provided in the Management's review is consistent with the financial statements.</g:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements><h:DescriptionOfPrimaryActivitiesOfEntity contextRef="c1">Orphazyme is dedicated to the development of a novel class of therapeutics for the treatment of genetic and degenerative diseases. Orphazyme's programs are in preclinic / clinical development as potential treatments for lysosomal storage diseases and other neurodegenerative diseases such as ALS.
Orphazyme's lead project is to develop new medicine for the treatment of lysosomal storage diseases, a family of more than 50 genetic disorders that occur in 1:10.000 births. The Company applies proprietary know-how and technology based on the cytoprotective properties of heat-shock proteins.
Arimoclomol effectively treats cells from patients suffering from different lysosomal storage diseases, for which there is no current treatment available. Arimoclomol has also exhibited therapeutic effect in animal disease models further substantiating its therapeutic potential. A clinical program in Niemann Pick disease type C, a debilitating and ultimately fatal lysosomal storage disease, is currently enrolling and patients will enter the interventional part with arimoclomol in 2016. Moreover, Arimoclomol is currently in clinical development in a genetically defined subpopulation of patients suffering from the motorneuron disease ALS and will start development in sIBM towards the end of 2016.</h:DescriptionOfPrimaryActivitiesOfEntity><h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="c1">The income statement for 2015 shows a loss of DKK 26,210,613 against a loss of DKK 31,958,124 last year, and the balance sheet at 31 December 2015 shows equity of DKK 75,025,888. Management considers the Company's financial performance in the year satisfactory.</h:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs><h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="c1">No significant events have occurred subsequent to the financial year.</h:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod><d:InformationOnReportingClassOfEntity contextRef="c1">The annual report of Orphazyme ApS for 2015 has been prepared in accordance with the provisions applying to reporting class B enterprises under the Danish Financial Statements Act.</d:InformationOnReportingClassOfEntity><d:InformationOnNoncomparabilityOrRestatement contextRef="c1">The income statement is now presented by function. Previously, the income statement was presented by nature.
In Management's opinion, these changes result in a more true and fair view of the Company's activities.
The changes have not affected the results of operations, equity or balance sheet total.
The Company changed its financial year to follow the calendar year. Current financial year covers only six months, while the comparative figures cover 12 months.
The financial statements have otherwise been presented in accordance with the same accounting policies as were applied last year. Comparative figures have been restated to reflect the policy change.</d:InformationOnNoncomparabilityOrRestatement><d:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="c1">Reporting currency
The financial statements are presented in Danish kroner.</d:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies><d:DescriptionOfMethodsOfForeignCurrencies contextRef="c1">On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or financial expenses.
Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and at the date at which the receivable or payable arose or was recognised in the latest financial statements is recognised in the income statement as financial income or financial expenses.</d:DescriptionOfMethodsOfForeignCurrencies><d:DescriptionOfMethodsOfLeases contextRef="c1">Leases that do not transfer substantially all the risks and rewards incident to the ownership to the Company are classified as operating leases. Payments relating to operating leases and any other leases are recognised in the income statement over the term of the lease. The Company's aggregate liabilities relating to operating leases and other leases are disclosed under contingencies, etc.</d:DescriptionOfMethodsOfLeases><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue contextRef="c1">Gross profit
In the income statement, revenue, production expenses and other operating income have been aggregated into one item called 'gross margin', cf. section 32 of the Danish Financial Statements Act.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses contextRef="c1">Administrative expenses include expenses incurred in the year for purposes of managing and administering the company, including expenses relating to administrative staff, management, office premises/expenses as well as amortisation/depreciation of assets used for administrative purposes.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfAdministrativeExpenses><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfResearchAndDevelopmentExpendituresRecognisedAsExpenses contextRef="c1">The item includes research costs not satisfying the criteria for capitalisation, including expenses relating to clinical trials, patent, staff costs, etc.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfResearchAndDevelopmentExpendituresRecognisedAsExpenses><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses contextRef="c1">Financial income and expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest income and expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="c1">Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.
Tax of the year includes tax credit for costs incurred in connection with research and development activities under the Danish Tax Credit Regime.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment contextRef="c1">Property, plant and equipment
Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. Cost includes the acquisition price and costs directly related to the acquisition until the time at which the asset is ready for use.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfPropertyPlantAndEquipment><d:DescriptionOfMethodsOfInvestments contextRef="c1">Rental deposits are measured at cost.</d:DescriptionOfMethodsOfInvestments><d:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets contextRef="c1">Intangible assets, property, plant and equipment and investments are subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation or amortisation. Impairment tests are conducted in respect of individual assets or groups of assets generating separate cash flows when there is indications of impairment. The assets are written down to the higher of the value in use and net realisable value (recoverable amount) of the asset or group of assets if this is lower than the carrying amount. As for group of assets, impairment losses are first recognised in respect of goodwill and thereafter proportionately in respect of the other assets.</d:DescriptionOfMethodsOfAmortisationOfNoncurrentAssets><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="c1">Receivables are measured at amortised cost.
An impairment loss is recognised if there is objective indication that a receivable or a group of receivables is impaired. If there is objective indication that an individual receivable has been impaired, write-down is made on an individual basis.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets contextRef="c1">Prepayments recognised under âAssets' comprise prepaid expenses regarding subsequent financial reporting years.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="c1">Cash at hand and in bank comprise cash and short-term marketable securities which are subject to an insignificant risk of changes in value.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="c1">Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account.
Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities, with the exception of temporary differences occuring at the time of acquisition and liablities neither effecting the result of operation nor the taxable income.
Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax><d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="c1">Other payables
Other payables are measured at net realisable value.</d:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions><d:InformationOnClassesOfIssuedShares contextRef="c1">The share capital of the Company is divided into 4 classes, an A class, a B class, a C class and a W class with a preferential position for the B and C class.
Until 6 January 2020, the Board of Directors shall be authorised to decide on one or more issues of warrants with the rights of subscription of 1 A share per warrant in the Company in the total amount of up to DKK 383,000 with addition of DKK 245,000 without pre-emptive subscription right for the Company's shareholders. The Board of Directors has issued a total of 462,701 warrants under the authorisation with a right to subscribe for up to nominally DKK 462,701 A shares. Consequently, warrants with a right to subscribe further A shares in the nominal amount of DKK 165,299 may be issued under the authorisation.
Any B and C share may at the request of its holder at any time be converted into an A share (Conversion rate 1:1). The Board is authorised to adopt any changes to the Articles of Association required to implement any conversion request.</d:InformationOnClassesOfIssuedShares><d:InformationOnExpensesIncurredInFormationOfEntityOrIncreaseInShareCapital contextRef="c1">In connection with the capital increase, the Company incurred expenses totalling DKK 30,000.</d:InformationOnExpensesIncurredInFormationOfEntityOrIncreaseInShareCapital><d:DisclosureOfCollateralsAndAssetsPledgesAsSecurity contextRef="c1">The Company has not placed any assets or other as security for loans at 31/12 2015.</d:DisclosureOfCollateralsAndAssetsPledgesAsSecurity><d:DisclosureOfLiabilitiesUnderLeases contextRef="c1">Other rent and lease liabilities:
DKK
2015
2015
Rent and lease liabilities
569,000
557,000
</d:DisclosureOfLiabilitiesUnderLeases><!--Aktuelle periode enkelt selskab--><context id="c1"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period></context><!--Forrige periode enkelt selskab--><context id="c4"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2014-07-01</startDate><endDate>2015-06-30</endDate></period></context><!--Slutdato forrige periode enkelt selskab--><context id="c5"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-06-30</instant></period></context><!--Slutdato aktuelle periode enkelt selskab--><context id="c7"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period></context><!--BOARD1--><context id="c33"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>1</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD2--><context id="c49"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>2</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD3--><context id="c50"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>3</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD4--><context id="c51"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>4</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD5--><context id="c52"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>5</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD6--><context id="c53"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>6</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD7--><context id="c54"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>7</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--BOARD8--><context id="c55"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfSupervisoryBoardDimension"><e:memberOfBoardIdentifier>8</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--Aktiespec Besk1--><context id="c72"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfClassOfSharesDimension"><d:classOfSharesIdentifier>1</d:classOfSharesIdentifier></xbrldi:typedMember></scenario></context><!--CEO1--><context id="c76"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfMemberOfExecutiveBoardDimension"><e:memberOfBoardIdentifier>1</e:memberOfBoardIdentifier></xbrldi:typedMember></scenario></context><!--REVISOR1--><context id="c106"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:typedMember dimension="e:IdentificationOfAuditorDimension"><e:auditorIdentifier>1</e:auditorIdentifier></xbrldi:typedMember></scenario></context><!--Overfoert resultat aktuel i aaret--><context id="c194"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="d:ResultDistributionDimension">d:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfoert resultat forrige i aaret--><context id="c195"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2014-07-01</startDate><endDate>2015-06-30</endDate></period><scenario><xbrldi:explicitMember dimension="d:ResultDistributionDimension">d:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel primo--><context id="c312"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-07-01</instant></period><scenario><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel i aaret--><context id="c313"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Virksomhedskapital aktuel ultimo--><context id="c314"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel primo--><context id="c351"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-07-01</instant></period><scenario><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel i aaret--><context id="c352"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Overfort res aktuel ultimo--><context id="c353"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:RetainedEarningsMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel primo forrige aar--><context id="c393"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:PreviousYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel i aaret forrige aar--><context id="c394"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:PreviousYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel ultimo forrige aar--><context id="c395"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:PreviousYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel primo forrige aar 2--><context id="c396"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:TwoYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel i aaret forrige aar 2--><context id="c397"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:TwoYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel ultimo forrige aar 2--><context id="c398"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:TwoYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel primo forrige aar 3--><context id="c399"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:ThreeYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel i aaret forrige aar 3--><context id="c400"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:ThreeYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel ultimo forrige aar 3--><context id="c401"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:ThreeYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel primo forrige aar 4--><context id="c402"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-07-01</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:FourYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel i aaret forrige aar 4--><context id="c403"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><startDate>2015-07-01</startDate><endDate>2015-12-31</endDate></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:FourYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Kapital aktuel ultimo forrige aar 4--><context id="c404"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-12-31</instant></period><scenario><xbrldi:explicitMember dimension="e:RetrospectiveInformationDimension">e:FourYearsAgoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="d:ClassesOfEquityDimension">d:ContributedCapitalMember</xbrldi:explicitMember></scenario></context><!--Aktiespec1 forrige ultimo--><context id="c1294"><entity><identifier scheme="http://www.dcca.dk/cvr">32266355</identifier></entity><period><instant>2015-06-30</instant></period><scenario><xbrldi:typedMember dimension="d:IdentificationOfClassOfSharesDimension"><d:classOfSharesIdentifier>1</d:classOfSharesIdentifier></xbrldi:typedMember></scenario></context><!--DKK enere--><unit id="u5"><measure>iso4217:DKK</measure></unit></xbrl>